Which has preferable earnings & valuation, BMEA or MDCX?

Biomea Fusion is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is BMEA or MDCX more profitable?

Biomea Fusion's return on equity of -265.37% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Medicus Pharma N/A -3,137.84% -311.33%

Do analysts rate SPRO or MDCX?

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,332.43%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer THAR or MDCX?

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,332.43%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better earnings and valuation, THAR or MDCX?

Tharimmune is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is THAR or MDCX more profitable?

Tharimmune's return on equity of -588.45% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Medicus Pharma N/A -3,137.84% -311.33%

Which has higher earnings & valuation, BTMD or MDCX?

biote has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $188.16M 0.46 $27.05M $0.44 5.18 Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is BTMD or MDCX more profitable?

biote has a net margin of 8.29% compared to Medicus Pharma's net margin of 0.00%. biote's return on equity of -25.72% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% Medicus Pharma N/A -3,137.84% -311.33%

Medicus Pharma (MDCX) Competitors

$0.37 -0.01 (-3.70%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.38 +0.01 (+2.70%)

As of 07/24/2026 07:34 PM Eastern

Compare

MDCX vs. BMEA, SPRO, THAR, HRTX, and BTMD

Should you buy Medicus Pharma stock or one of its competitors? MarketBeat compares Medicus Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medicus Pharma include Biomea Fusion (BMEA), Spero Therapeutics (SPRO), Tharimmune (THAR), Heron Therapeutics (HRTX), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does Medicus Pharma compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Biomea Fusion's return on equity of -265.37% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Biomea Fusion is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Biomea Fusion has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

96.7% of Biomea Fusion shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Medicus Pharma had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 1.89 beat Medicus Pharma's score of 0.47 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Overall Sentiment
Biomea Fusion	Very Positive
Medicus Pharma	Neutral

Biomea Fusion currently has a consensus price target of $8.50, indicating a potential upside of 580.00%. Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,332.43%. Given Medicus Pharma's higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Biomea Fusion beats Medicus Pharma on 8 of the 13 factors compared between the two stocks.

How does Medicus Pharma compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Spero Therapeutics has a net margin of 24.90% compared to Medicus Pharma's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market.

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,332.43%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

25.6% of Spero Therapeutics shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Spero Therapeutics has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.03	$8.57M	$0.24	4.96
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

In the previous week, Spero Therapeutics had 1 more articles in the media than Medicus Pharma. MarketBeat recorded 3 mentions for Spero Therapeutics and 2 mentions for Medicus Pharma. Spero Therapeutics' average media sentiment score of 1.12 beat Medicus Pharma's score of 0.47 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Positive
Medicus Pharma	Neutral

Summary

Spero Therapeutics beats Medicus Pharma on 11 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Tharimmune has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,332.43%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Tharimmune's return on equity of -588.45% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Tharimmune is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

In the previous week, Medicus Pharma had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.25 beat Medicus Pharma's score of 0.47 indicating that Tharimmune is being referred to more favorably in the media.

Company	Overall Sentiment
Tharimmune	Positive
Medicus Pharma	Neutral

1.2% of Tharimmune shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Medicus Pharma beats Tharimmune on 7 of the 13 factors compared between the two stocks.

How does Medicus Pharma compare to Heron Therapeutics?

Medicus Pharma (NASDAQ:MDCX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Medicus Pharma has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Heron Therapeutics has higher revenue and earnings than Medicus Pharma. Heron Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Heron Therapeutics	$150.71M	0.57	-$20.19M	-$0.18	N/A

Medicus Pharma has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Medicus Pharma's return on equity of -3,137.84% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

80.0% of Heron Therapeutics shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Medicus Pharma had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Medicus Pharma's score of 0.47 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Medicus Pharma	Neutral
Heron Therapeutics	Very Positive

Medicus Pharma presently has a consensus price target of $9.00, indicating a potential upside of 2,332.43%. Heron Therapeutics has a consensus price target of $2.50, indicating a potential upside of 448.49%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Medicus Pharma and Heron Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Medicus Pharma compare to biote?

biote (NASDAQ:BTMD) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

biote has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$188.16M	0.46	$27.05M	$0.44	5.18
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

In the previous week, biote and biote both had 2 articles in the media. biote's average media sentiment score of 0.94 beat Medicus Pharma's score of 0.47 indicating that biote is being referred to more favorably in the media.

Company	Overall Sentiment
biote	Positive
Medicus Pharma	Neutral

biote currently has a consensus target price of $2.75, suggesting a potential upside of 20.61%. Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,332.43%. Given Medicus Pharma's higher probable upside, analysts plainly believe Medicus Pharma is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

biote has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

21.7% of biote shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

biote has a net margin of 8.29% compared to Medicus Pharma's net margin of 0.00%. biote's return on equity of -25.72% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Summary

biote beats Medicus Pharma on 13 of the 15 factors compared between the two stocks.

Get Medicus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDCX vs. The Competition

Export

Metric	Medicus Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.77M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.14	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.06	88.99
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	N/A	7.88	10.28	6.07
Net Income	-$35.46M	$23.86M	$3.60B	$331.99M
7 Day Performance	-1.54%	-3.82%	-1.27%	-0.63%
1 Month Performance	-16.85%	-2.61%	-0.37%	-2.00%
1 Year Performance	-87.37%	32.79%	18.30%	13.62%

Medicus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDCX Medicus Pharma	1.8973 of 5 stars	$0.37 -3.7%	$9.00 +2,332.4%	-87.7%	$21.77M	N/A	N/A	N/A	Short Interest Increase
BMEA Biomea Fusion	3.2907 of 5 stars	$1.26 -2.3%	$8.50 +574.6%	-30.9%	$91.10M	N/A	N/A	50
SPRO Spero Therapeutics	1.6493 of 5 stars	$1.57 -7.6%	N/A	-49.4%	$90.90M	$66.80M	6.54	150	News Coverage High Trading Volume
THAR Tharimmune	0.0757 of 5 stars	$2.39 +3.9%	N/A	+34.6%	$90.18M	N/A	N/A	2	Gap Up
HRTX Heron Therapeutics	1.9804 of 5 stars	$0.48 +8.4%	$2.50 +425.2%	-76.0%	$90.10M	$150.71M	N/A	300	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDCX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicus Pharma (MDCX) Competitors

MDCX vs. BMEA, SPRO, THAR, HRTX, and BTMD

How does Medicus Pharma compare to Biomea Fusion?

Summary

How does Medicus Pharma compare to Spero Therapeutics?

Summary

How does Medicus Pharma compare to Tharimmune?

Summary

How does Medicus Pharma compare to Heron Therapeutics?

Summary

How does Medicus Pharma compare to biote?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medicus Pharma (MDCX) Competitors

MDCX vs. BMEA, SPRO, THAR, HRTX, and BTMD

How does Medicus Pharma compare to Biomea Fusion?

Is BMEA or MDCX more profitable?

Which has preferable earnings & valuation, BMEA or MDCX?

Which has more volatility and risk, BMEA or MDCX?

Do insiders & institutionals have more ownership in BMEA or MDCX?

Does the media refer more to BMEA or MDCX?

Do analysts rate BMEA or MDCX?

Summary

How does Medicus Pharma compare to Spero Therapeutics?

Is SPRO or MDCX more profitable?

Which has more volatility & risk, SPRO or MDCX?

Do analysts rate SPRO or MDCX?

Do insiders and institutionals believe in SPRO or MDCX?

Which has better valuation and earnings, SPRO or MDCX?

Does the media refer more to SPRO or MDCX?

Summary

How does Medicus Pharma compare to Tharimmune?

Which has more risk & volatility, THAR or MDCX?

Do analysts prefer THAR or MDCX?

Is THAR or MDCX more profitable?

Which has better earnings and valuation, THAR or MDCX?

Does the media refer more to THAR or MDCX?

Do insiders & institutionals hold more shares of THAR or MDCX?

Summary

How does Medicus Pharma compare to Heron Therapeutics?

Which has more risk & volatility, MDCX or HRTX?

Which has stronger earnings & valuation, MDCX or HRTX?

Is MDCX or HRTX more profitable?

Do insiders and institutionals have more ownership in MDCX or HRTX?

Does the media prefer MDCX or HRTX?

Do analysts rate MDCX or HRTX?

Summary

How does Medicus Pharma compare to biote?

Which has higher earnings & valuation, BTMD or MDCX?

Does the media favor BTMD or MDCX?

Do analysts prefer BTMD or MDCX?

Which has more volatility and risk, BTMD or MDCX?

Do institutionals & insiders hold more shares of BTMD or MDCX?

Is BTMD or MDCX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools